What is Pardes Biosciences Forward Dividend Yield %?
As of today (2024-05-27), the Forward Annual Dividend Yield of Pardes Biosciences is 0.00%.
As of today (2024-05-27), the Trailing Annual Dividend Yield of Pardes Biosciences is 0.00%.
PRDS's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.63 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Pardes Biosciences's Forward Dividend Yield %
For the Biotechnology subindustry, Pardes Biosciences's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pardes Biosciences's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pardes Biosciences's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Pardes Biosciences's Forward Dividend Yield % falls into.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Pardes Biosciences Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Pardes Biosciences's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Pardes Biosciences (Pardes Biosciences) Business Description
Pardes Biosciences Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel oral-antiviral therapeutics to improve the lives of patients suffering from life-threatening disease, starting with the lead product candidate, pomotrelvir (formerly known as PBI-0451), which is in clinical development and intended to treat COVID-19 in adult and pediatric patients. COVID-19 is caused by infection with the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Pomotrelvir inhibits the main coronaviral cysteine protease, a viral protein essential for the replication of all known coronaviruses, including SARS-CoV-2.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRDS has been successfully added to your